ClinicalTrials.gg
CompletedNCT03450330JACKPOT1Updated Aug 24, 2020

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

A Phase 1/2 interventional study of AZD4205 in Nonsmall Cell Lung Cancer, sponsored by Dizal Pharmaceuticals. Completed at 4 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-24.

Sponsored by Dizal Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals — 6 open to participants now, 9 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Dizal Pharmaceuticals.

Enrollment
12th of 12
10 · median 160
Started
2018
the only one that year
Phase 1/2
4 of 12
2 open now
Registered
1st of 12
by date

Among the 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals, this one is the 12th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 1/2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals, or all of them as a file.
02

Study summary

This study will treat patients with advanced NSCLC who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy and in combination with Osimertinib.

Read the detailed description

A phase I/II, open-label, multicentre study to investigate the safety, tolerability, pharmacokinetics and anti-tumour activity of AZD4205 as monotherapy or in combination with Osimertinib in patients with EGFR mutant advanced stage non-small cell lung cancer (NSCLC). This study includes dose escalation part and dose expansion part.

03

Conditions studied

  • Nonsmall Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Obtained written
  2. Patients must have histological or cytological confirmation of activating EGFR mutation positive NSCLC and have failed prior EGFR TKIs treatment.
  3. Patients must exhibit (ECOG) performance status 0-1
  4. Adequate bone marrow reserve and organ system functions

Exclusion criteria

Exclusion Criteria:

  1. Any unsolved toxicity > grade 1 from previous anti-cancer therapy (except alopecia)
  2. Active viral or bacterial infections;
  3. Active or latent tuberculosis;
  4. History of interstitial lung disease (ILD)
  5. History of heart failure or prolongation
  6. Immunodeficiency diseases;
  7. Active
  8. Treatment with an EGFR TKI (e.g., erlotinib or gefitinib) within 8 days or approximately 5 x half-life, whichever is longer, of the first dose of study treatment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    daily dose of AZD4205

    daily dose of AZD4205

    Drug: AZD4205

Interventions

  • Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.

This study also gives Osimertinib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. safety and tolerability of AZD4205

    Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v4.0

    Time frame: 21 days after the first dose

Secondary outcomes

  1. Objective Response Rate (ORR)

    Per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (by investigator assessment) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.

    Time frame: RECIST tumour assessments every 6 weeks from enrollment until study completion, an average of 1 year

  2. Peak Plasma Concentration (Cmax) of AZD4205

    Peak Plasma Concentration (Cmax) of AZD4205

    Time frame: 1,8,15 days after first dose

  3. Area under the plasma concentration versus time curve (AUC) of AZD4205

    Area under the plasma concentration versus time curve (AUC) of AZD4205

    Time frame: 1,8,15 days after first dose

07

Study locations

4 sites
  • St George Hospital
    Sydney, New South Wales, Australia
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria, Australia
  • Northern Cancer Institute St Leonards
    Sydney, 2066, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Sep 2019, 16 months.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 16 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2018
First posted
Mar 1, 2018
StartActual
Apr 16, 2018
Primary completionActual
Sep 3, 2019
CompletionActual
Jan 10, 2020
Last update
Aug 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03450330
Responsible party
Sponsor
First posted
Mar 1, 2018
Start date
Apr 16, 2018
Primary completion
Sep 3, 2019
Completion
Jan 10, 2020
Last update
Aug 24, 2020

Study contacts

Pamela Yang, MD, PhD
study director · Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golidocitinib

Start the discussion